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Hendra virus and Nipah virus are bat-borne paramyxoviruses that are the prototypic members of the
genus Henipavirus. The henipaviruses emerged in the 1990s, spilling over from their natural bat hosts
and causing serious disease outbreaks in humans and livestock. Hendra virus emerged in Australia and
since 1994 there have been 7 human infections with 4 case fatalities. Nipah virus ﬁrst appeared in Malay-
sia and subsequent outbreaks have occurred in Bangladesh and India. In total, there have been an esti-
mated 582 human cases of Nipah virus and of these, 54% were fatal. Their broad species tropism and
ability to cause fatal respiratory and/or neurologic disease in humans and animals make them important
transboundary biological threats. Recent experimental ﬁndings in animals have demonstrated that a
human monoclonal antibody targeting the viral G glycoprotein is an effective post-exposure treatment
against Hendra and Nipah virus infection. In addition, a subunit vaccine based on the G glycoprotein of
Hendra virus affords protection against Hendra and Nipah virus challenge. The vaccine has been devel-
oped for use in horses in Australia and is the ﬁrst vaccine against a Biosafety Level-4 (BSL-4) agent to
be licensed and commercially deployed. Together, these advances offer viable approaches to address
Hendra and Nipah virus infection of livestock and people.
 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-SA license.1. Introduction
Hendra virus and Nipah virus are recently recognized bat-borne
paramyxoviruses, each of which have repeatedly emerged causing
signiﬁcant morbidity and mortality in both animal and human
populations since the mid to late 1990’s. Hendra virus was isolated
in Australia from fatal cases of severe respiratory disease in horses
and one person in the Brisbane suburb of Hendra in September,
1994, and was shown to be distantly related to measles virus
and other morbilliviruses (Murray et al., 1995). The same virushad also caused fatal infections in horses a month prior in Mackay,
Australia, but this emergence was only recognized when one indi-
vidual who was unknowingly exposed to the infected horses at
that time developed a recrudescence of fatal meningoencephalitis
13 months later (O’Sullivan et al., 1997; Wong et al., 2009). Hendra
virus’ close relative, Nipah virus, emerged in peninsular Malaysia
in 1998–99, in a large outbreak of respiratory disease in pigs along
with numerous cases of encephalitis among pig farmers, eventu-
ally resulting in more than 100 human fatalities. Genetic and sero-
logical studies revealed the relatedness of this new virus to Hendra
virus (Chua et al., 2000). Hendra virus and Nipah virus now repre-
sent the prototype species of the new genus Henipaviruswithin the
paramyxovirus family (Wang et al., 2013).
Since their discovery, both Hendra virus and Nipah virus have
continued to repeatedly cause spillover events into animals and/
or people. Hendra virus infection among horses in Australia has oc-
curred annually since 2006 and in total there have now been 7 hu-
man cases of which 4 have been fatal (Anonymous, 2009b;
Playford et al., 2010). In all 7 human cases, Hendra virus was trans-
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months of June to October, a signiﬁcant increase in the number of
Hendra virus spillovers occurred with 18 separate episodes of
infection in horses in Australia, including the ﬁrst recognized case
of infection in a dog (reviewed in (Broder, 2012)). There were
8 cases of Hendra virus spillovers into horses in 2012 (Anonymous,
2012b) and a further two cases of Hendra virus infection in horses
in early 2013 (Anonymous, 2013b). In all, a total of 42 Hendra virus
spillover events have occurred since 1994 and 28 of these have oc-
curred in just the past 2 years. Likewise, following the Malaysian
outbreak in 1998, nearly annual outbreaks of Nipah virus infection,
occurring primarily in Bangladesh but also India have occurred
since 2001. The most recent outbreak occurred in early 2013, with
apparently 10 fatalities of 12 cases (Anonymous, 2013c). Compared
to the original Malaysian outbreak, these Nipah virus spillovers
have been smaller in case number, however the fatality rates in
people overall have been notably higher, ranging from 75–100%.
Importantly, direct transmission of Nipah virus from bats to hu-
mans and signiﬁcant human-to-human transmission have also
been documented during outbreaks in India and Bangladesh. The
epidemiological details of the spillovers of both Hendra virus and
Nipah virus into people since their emergence and recognition
have recently been reviewed and summarized in detail (Luby and
Gurley, 2012). There have been an estimated 582 cases of
Nipah virus infection with 315 human fatalities (Anonymous,
2013c; Luby and Gurley, 2012; Luby et al., 2009; Pallister et al.,
2011a).2. The henipavirus transboundary threat
The natural reservoir hosts of Hendra virus and Nipah virus are
several species of pteropid fruit bats among which they are not
known to cause disease (Halpin et al., 2011). However, Hendra
and Nipah viruses possess an exceptionally broad species tropism
and both natural and experimental infections have demonstrated
their capacity to cause disease which can often be fatal in horses,
pigs, cats, dogs, ferrets, hamsters, guinea pigs, monkeys, and
humans, spanning 6 mammalian Orders (reviewed in (Geisbert
et al., 2012)). In disease susceptible animal hosts and people,
Nipah virus and Hendra virus cause a systemic infection that is
characterized as a wide-spread vasculitis and endothelial cell tro-
pism. Though this pathology is not unique to these henipaviruses,
an understanding of Hendra and Nipah virus cellular tropism on
the molecular level has provided an explanation to this disease
feature which includes the appearance of syncytia, thrombosis,
ischemia and necrosis, with parenchymal cell infection and asso-
ciated pathology in many major organ systems, and prominently
in the brain and lung (reviewed in (Weingartl et al., 2009; Wong
and Ong, 2011)). The major involvement of the lung and brain in
Hendra and Nipah virus infection often manifests as an acute se-
vere respiratory syndrome, encephalitis or a combination of both.
Disturbingly however, infection in people can also have longer
term consequences, and in addition to an acute symptomatic
infection, Hendra and Nipah virus infection can also take a pro-
tracted course following recovery from an initial infection. Indi-
viduals in these cases can later undergo a recrudescence of virus
replication in the central nervous system (CNS) causing a relapse
of encephalitis, a process that was ﬁrst noted in the second fatal
case of Hendra virus human infection (O’Sullivan et al., 1997;
Wong et al., 2009). Quite remarkably, relapsed-encephalitis
caused by Nipah virus has been reported in people from several
months to as long as 11 years following infection (Abdullah
et al., 2012) (reviewed in (Wong, 2010)). How the henipaviruses
survive immune-mediated clearance and can later cause a recru-
descence of replication in the CNS is unknown, but this virologicalfeature clearly has important implications for anti-henipavirus
therapeutics development.
Given the virulence of Hendra and Nipah virus and the increase
in their spillover occurrences over the past decade, strategies to
mitigate the risk of Hendra and Nipah virus exposure have be-
come paramount. Both Hendra virus and Nipah virus reside in
large wild bat populations, which make controlling virus in the
reservoir host or inﬂuencing the reservoir host population dynam-
ics difﬁcult to impossible. In extreme instances, bat culling has
been proposed to minimize exposure; however, the ecological
importance of bats as a whole makes this an unrealistic option.
In Malaysia and Australia efforts have been made to reduce
livestock interactions with bats; for example, restricting livestock
access to areas under fruit trees, covering water and feed contain-
ers to prevent contamination and not placing water and feed un-
der fruit trees (Anonymous, 2013a). However, the signiﬁcant
numbers of fruit trees and roosting ﬂying foxes on or near prop-
erties containing livestock makes complete separation of the wild-
life and livestock populations near impossible. In Bangladesh,
measures have been employed to prevent ﬂying foxes access to
date palm sap collectors in hopes of preventing contamination
with Nipah virus (Luby and Gurley, 2012). Unfortunately, Nipah
outbreaks continue to occur every year reﬂecting the difﬁculty
of implementing a new practice culturally to prevent such a dis-
ease that is still considered to be rare. Developing vaccines and
antiviral therapies for Hendra and Nipah virus are also viable
alternatives for mitigating disease risk. As livestock have been
identiﬁed as intermediate hosts for both Hendra and Nipah virus,
antiviral therapies seem less attractive given the size of horses
and pigs and the signiﬁcant costs associated with producing large
quantities of any possible drug. Conversely, vaccination of live-
stock populations is a highly attractive mitigation strategy since
both disease in the target species as well as secondary transmis-
sion of virus to humans would be prevented. In areas such as
Bangladesh, where no intermediate host has been deﬁnitively
identiﬁed, there is a real need for the development of effective
therapies and vaccine strategies to prevent infection. Similarly,
for individuals who have potential occupational exposure to
Hendra and Nipah virus infection, such as pig farmers and equine
veterinarians, therapeutic agents and/or a vaccine to prevent
infection would signiﬁcantly reduce morbidity and mortality asso-
ciated with Hendra and Nipah viruses.
Hendra and Nipah virus attach to host cell-surface displayed
ephrin-B2 or -B3 proteins and infect host cells by the coordinated
activity of their attachment (G) and fusion (F) glycoproteins (re-
viewed in (Aguilar and Iorio, 2012; Lee and Ataman, 2011)). The
G glycoprotein monomer consists of a stalk and globular head
(Fig. 1) and the atomic structures of both the Nipah and Hendra
virus G glycoprotein’s globular head domain have been determined
alone and in complex with ephrin proteins (reviewed in (Xu et al.,
2012a)). The F glycoprotein mediates the membrane fusion process
between the viral and host cell membranes by a Class I fusion
mechanism that is initiated following the G glycoprotein
engagement of ephrin receptor (Lee and Ataman, 2011). The sus-
ceptible host species and associated cellular tropism and pathology
of Hendra and Nipah virus has in large part been explained by their
use of the highly conserved ephrin-B2 and -B3 proteins as entry
receptors (reviewed in (Pernet et al., 2012; Wong and Ong,
2011)). In addition and of importance to countermeasure develop-
ment, the henipavirus G and F envelope glycoprotein spikes are
major targets of virus-neutralizing antibodies and as discussed be-
low, the development of potential vaccines have largely focused on
these important structural components of the virion (reviewed in
(Broder, 2010)).
The development of medical countermeasures for use in hu-
mans is a time-consuming process, especially for highly pathogenic
Fig. 1. Model of the Hendra virus soluble G glycoprotein subunit vaccine (HeV-sG) and its complex with the henipavirus-neutralizing human monoclonal antibody m1024.
(A) The HeV-sG glycoprotein subunit vaccine is composed of the entire ectodomain (amino acids 76–604) of the HeV G glycoprotein. Here, HeV-sG is shown as dimer with one
monomer colored green and the other cyan. The secondary structure elements of the two globular head domains are derived from the crystal structure of the HeV G head
domain (Colgrave et al., 2011; Xu et al., 2012b), and the stalk regions of each G monomer (residues 77–136) are modeled (Kelley and Sternberg, 2009). N-linked glycosylation
sites shown as gray spheres. The ephrin-binding face of the cyan globular head is facing forward with an overlay of the interacting ephrin-B2 G-H loop residues in yellow. (B)
The HeV-sG dimer shown in complex with two m102.4 Fab antibody fragments. The two HeV-sG monomers are colored green and cyan as in panel A and rotated slightly to
the right. The two Fab m102.4 molecules are shown with their heavy chains colored in magenta and light chain – in yellow, each binding one globular head domains of G. (Xu,
K. et al., submitted). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.).
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trials are not feasible. Demonstrated efﬁcacy in two animal models
of disease is required to support possible licensure. In recent years
monoclonal antibodies (mAbs) have attracted considerable atten-
tion as viable antiviral and antibacterial therapies, and the Food
and Drug Administration (FDA) has approved both humanized
and fully human monoclonal antibody (mAb) for use in preventing
or treating infectious diseases in humans (Dolgin, 2013; Zhu et al.,
2013). The development of human monoclonal antibodies (hum-
Abs) against Hendra and Nipah virus infection has been highly suc-
cessful and as discussed below, a viable post-exposure mAb
therapy is currently in development. In addition, a recombinant
subunit vaccine candidate has been successfully trialed in several
animal challenge models of Hendra and Nipah virus infection,
and has recently been deployed as an effective equine vaccine in
Australia; potentially breaking the chain of Hendra virus transmis-
sion and a practical cost effective way to mitigate human Hendra
virus infection.
3. Antiviral treatment
There are no approved or licensed therapeutics for treating hen-
ipavirus infection or disease in people, and antiviral approaches
against the henipaviruses that have been tested in animal models
are few (reviewed in (Broder, 2012)). Ribavirin is a well-known
ﬁrst line treatment strategy for suspected viral infections of un-
known etiology. Ribavirin exhibits antiviral activity against a wide
variety of both RNA and some DNA viruses (Sidwell et al., 1972)
and is an accepted or approved treatment for several viral infec-
tions including respiratory syncytial virus and arenaviral hemor-
rhagic-fevers (reviewed in (Snell, 2001)). In vitro studies have
shown that ribavirin is effective against both Hendra and Nipah
virus replication (Aljofan et al., 2009; Wright et al., 2005). Also,
the anti-malarial drug chloroquine was shown earlier to blockthe critical proteolytic processing needed for the maturation and
function of the Hendra virus F glycoprotein (Pager et al., 2004),
and not surprisingly cholorquine was later shown to inhibit Nipah
and Hendra virus infection in cell culture (Porotto et al., 2009).
An open label ribavirin treatment trial was carried out during
the outbreak of Nipah virus in Malaysia in 1998 and was reported
to reduce mortality by 36% in treated patients when compared to
those patients who presented before ribavirin availability or who
refused treatment (Chong et al., 2001). Of the recorded human
Hendra virus cases, three individuals were treated with ribavirin,
and of these, two succumbed to disease and one survived (Playford
et al., 2010). Chloroquine was administered along with ribavirin to
one HeV-infected individual in 2009 (Anonymous, 2009c) with no
apparent clinical beneﬁt. Three additional people received ribavirin
treatment in combination with chloroquine after suspected expo-
sure to Hendra virus contaminated secretions from infected horses.
While all three individuals survived, infection was not conﬁrmed
and therefore it remains unknown whether the treatment had
any effect (Anonymous, 2009a). In the absence of other therapies,
ribavirin may be an option for treatment of henipavirus infections.
However, more recent animal studies have revealed no therapeutic
beneﬁt of either drug. Two studies in hamsters and one study in
nonhuman primates (African green monkey (AGM)) showed that
ribavirin treatment only delayed but did not prevent death after
Nipah or Hendra virus infection (Freiberg et al., 2010; Georges-
Courbot et al., 2006; Rockx et al., 2010) and AGMs treated with
ribavirin following Hendra virus infection had marked increases
of neurological symptoms. Similarly, chloroquine was unable to
prevent Nipah infection or disease in ferrets (Pallister et al., 2009).
4. A passive immunotherapy for people
In contrast, passive immunotherapy with polyclonal or mono-
clonal antibody speciﬁc for the viral envelope glycoproteins has
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eral studies carried out in hamsters (Guillaume et al., 2004, 2006).
Presently, the only reported and effective post-exposure therapy
against Hendra or Nipah virus infection and one that could likely
be approved in the near future for use in people has been a human
monoclonal antibody (mAb) known as m102.4 which was isolated
from a recombinant naïve human phage-displayed Fab library (Zhu
et al., 2008).
The m102.4 mAb has exceptionally potent neutralizing activity
against both Nipah and Hendra viruses and its epitope maps to the
ephrin receptor binding site (Fig. 1). Testing of m102.4 has con-
ﬁrmed its neutralization activity against several isolates; NiV-
Malaysia, HeV-1994, HeV-Redlands, NiV-Bangladesh (Bossart
et al., 2009). Effective post-exposure efﬁcacy with m102.4 has
now been demonstrated in both ferrets and nonhuman primates
(African green monkey (AGM)) infected with either Hendra virus
or Nipah virus (Table 1). The successful m102.4 passive immuno-
therapy in the AGM was recently reported in a study designed
to reﬂect a possible real life scenario requiring mAb as a post-
exposure treatment, and was a follow-up from the initial success-
ful m102.4 post-exposure therapy carried out in ferrets (Bossart
et al., 2009). Fourteen monkeys were challenged intratracheally
with Hendra virus and 12 animals were infused twice with a
100 mg dose (20 mg/kg) of m102.4 beginning at 10 h, 24 h or
72 h p.i. with the second infusion 48 h later. All 12 animals that
received m102.4 survived infection; whereas the untreated control
subjects succumbed to severe systemic disease by day 8 (Bossart
et al., 2011). There was no evidence of Hendra virus mediated
pathology in any of the m102.4-treated animals and no infectious
Hendra virus could be recovered from any tissues from any
m102.4-treated subjects.
In May of 2010, an instance of possible Hendra virus infection
in two individuals was reported on the Sunshine Coast, north of
Brisbane, Australia. Both individuals had extensive close contact
with a horse just prior to and during the development of clinical
illness in the animal. Following a diagnosis of Hendra virus infec-
tion in the horse, both individuals were considered to have had
high-risk exposure to Hendra virus (Anonymous, 2010). A request
was made by Australian health authorities to obtain m102.4 as a
possible compassionate use therapeutic option even though clini-
cal trials in human had not been undertaken and safety data of
the mAb in humans was lacking. These two individuals were
administered the m102.4 mAb (Miles, 2010). Both individuals ulti-
mately did not develop detectable Hendra virus infection but
whether this was due to the mAb therapy could not be determined.
In 2010, the cell line expressing the human m102.4 mAb was pro-
vided to the Queensland Government, Queensland Health, to allow
health authorities to manufacture m102.4 for its potential use on a
compassionate basis in future cases of high-risk human exposure.
In 2012, a third asymptomatic individual who experienced high-
risk Hendra virus exposure was also given m102.4 mAb therapyTable 1
Evaluation of post-exposure therapy with the henipavirus G glycoprotein-speciﬁc human m
Virus Animal
model
Experimental design and resultsa
Hendra AGM A 10, 24, or 72 h post-exposure use of m102.4 could protect
Ferret A 10 or 24 h post-exposure dose of m102.4 could protect a
Nipah Ferret A 10 h post-exposure dose of m102.4 could protect agains
AGM A 24, 72, or 120 h post-exposure use of m102.4 could prot
challenge
a The administration of m102.4 mAb was performed by infusion in all studies with
peritoneal injection (Bossart et al., 2009). All studies to date have reported that all animal
varying levels of mild to moderate illness.(Anonymous, 2012a; Guest, 2012). There have been no adverse
effects observed or reported in these cases.
5. A one-health solution – vaccination
Initial immunization strategies using the henipavirus G or F
viral glycoproteins were ﬁrst evaluated using recombinant vaccinia
viruses providing evidence that complete protection from disease
was achievable by eliciting an immune response to the Nipah virus
envelope glycoproteins (Guillaume et al., 2004). Other studies
using recombinant canarypox-based vaccine candidates for poten-
tial use in pigs have also been carried out (Weingartl et al., 2006).
To date, the most widely evaluated henipavirus vaccine antigen
has been a subunit, consisting of a recombinant soluble and oligo-
meric form of the G glycoprotein (sG) of Hendra virus (HeV-sG)
(Bossart et al., 2005). The HeV-sG subunit vaccine (Fig. 1) is a se-
creted version of the molecule in which the transmembrane and
cytoplasmic tail domains have been deleted from the coding se-
quence. HeV-sG is produced in mammalian cell culture expression
systems and is properly N-linked glycosylated and retains many
native characteristics including its oligomerization into dimers
and tetramers, ability to bind ephrin receptors and elicit potent
cross-reactive (Hendra and Nipah virus) neutralizing antibody re-
sponses (reviewed in (Broder et al., 2012)) Table 2.
Studies showing the HeV-sG subunit immunogen as a success-
ful vaccine against lethal Hendra virus or Nipah virus challenge
have been carried out in the cat (McEachern et al., 2008; Mungall
et al., 2006), ferret (Pallister et al., 2011b) and nonhuman primates
(Bossart et al., 2012) (Table 2), and details of the results from these
studies have been reviewed elsewhere (Broder et al., 2012). The
success of the HeV-sG vaccine-mediated protection observed in
multiple animal challenge models led to the consideration of the
HeV-sG as a safe and effective vaccine for horses against Hendra
virus infection in Australia following a human fatality in 2009
and the human exposure cases in 2010 discussed above. The
adopted equine vaccination strategy was to both prevent infection
in horses and thus ameliorate the risk of Hendra virus transmission
to people. A series of horse HeV-sG vaccination and Hendra virus
challenge studies have been carried out in Australia; at the high
containment biological safety level 4 (BSL-4) facilities of the
Animal Health Laboratories (AAHL), Commonwealth Scientiﬁc
and Industrial Research Organisation (CSIRO), in Geelong. The
development of HeV-sG as an equine vaccine against Hendra virus
was a collaborative research program between the Uniformed
Services University of the Health Sciences, the Henry M. Jackson
Foundation, the AAHL and Pﬁzer Animal Health (now Zoetis,
Inc.). Findings from these initial studies were reported at Austra-
lian Veterinary Association, Annual Conference in Adelaide, in
May 2011 (Balzer, 2011). The HeV-sG subunit glycoprotein was
used to vaccinate horses (a 2 dose regime with a 3 week interval)
and both a high and a low dose of HeV-sG antigen was examined.onoclonal antibody m102.4 against lethal henipavirus challenge in laboratory animals.
Reference
against a 10-fold lethal intratracheal virus challenge (Bossart et al., 2011)
gainst a 10-fold lethal oronasal virus challenge (Pallister J., unpublished)
t a 10-fold lethal oronasal virus challenge (Bossart et al., 2009)
ect against a 10-fold lethal intratracheal virus (Geisbert T.,
unpublished)
the exception of one ferret in one study were it had to be administered by intra-
s receiving m102.4 post-exposure therapy have survived virus challenge, some with
Table 2
Evaluation of the protective efﬁcacy of henipavirus sG vaccines against lethal henipavirus challenge in laboratory animals.
Virus Animal
model
Experimental design and resultsa Reference
Hendra Ferret Hendra-sG used to immunize followed by 10-fold lethal oronasal virus challenge (Pallister et al., 2011b)
AGM Hendra-sG used to immunize followed by 10-fold lethal intratracheal virus challenge (Bossart et al., 2012)
Horse Hendra-sG is used to immunize horses followed by lethal oronasal virus challenge (Balzer, 2011) (Middleton
D., et al., submitted)
Nipah Cat Hendra-sG or Nipah-sG used to immunize followed by 10-fold lethal subcutaneous virus challenge; Hendra-sG
used to immunize followed by 100-fold lethal oronasal virus challenge
(McEachern et al., 2008;
Mungall et al., 2006)
Ferret Hendra-sG used to immunize followed by 10-fold lethal oronasal virus challenge (Pallister J., unpublished)
AGM Hendra-sG used to immunize followed by 10-fold lethal intratracheal virus challenge (Geisbert T., unpublished)
a All studies to date have reported that all Hendra-sG immunized animals can be completely protected from infection and disease following either a Hendra or Nipah virus
challenge. No evidence of virus replication or shedding has been reported in the majority of challenged subjects.
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vaccinated horses remained clinically disease-free, and there was
no evidence of virus replication or virus shedding in any of the
immunized horses. On November 1, 2012, the vaccine called Equi-
vac HeV was released for use in Australia, and it is the ﬁrst vac-
cine licensed and commercially deployed against a BSL-4 agent
and currently is the only licensed prophylactic treatment for
henipaviruses.
6. Concluding remarks
The Nipah virus and Hendra virus are zoonotic paramyxoviruses
that can infect and cause lethal disease across a broad range of ver-
tebrate species including humans. They are present in a variety of
bat reservoirs, can be isolated and propagated and because of their
associated high morbidity and mortality they pose a risk from nat-
ural outbreaks, laboratory accidents or deliberate misuse. For all of
these reasons, the development of effective prevention and treat-
ment strategies has been pursued. Over the past decade a consid-
erable amount of research has focused on the henipavirus
envelope glycoproteins and their roles in the virus attachment
and infection process. These efforts have now led to the develop-
ment and testing of both passive and active immunization strate-
gies applicable to both human and animal use. Presently, a cross-
reactive human mAb (m102.4) has been demonstrated as an
exceptionally efﬁcacious post-exposure therapy in protecting both
ferrets and nonhuman primates from lethal henipavirus disease,
and its effectiveness led to its application in people as a compas-
sionate use post-exposure prophylaxis in Australia. Also, as an ac-
tive vaccination strategy for preventing Hendra virus infection and
disease in horses in Australia and thus blocking potential transmis-
sion to people, a recombinant subunit vaccine, HeV-sG, which has
been shown to provide protection against henipavirus challenge in
cats, ferrets, monkeys and now horses, has been licensed and de-
ployed for use in Australia.
To date, henipavirus antivirals have only been deployed in
Australia in the ﬁght against Hendra virus. As Nipah virus causes
signiﬁcantly more instances of human disease, increased efforts
are needed to advance Nipah-targeted countermeasures in ende-
mic regions. Animal models have demonstrated that both the
HeV-sG vaccine and the m102.4 human antibody can prevent both
Nipah virus infection and/or disease. Efforts are currently under
way to develop HeV-sG for human use as well as for use in pigs.
However, the cost of the vaccine per animal and uptake of the vac-
cine in the absence of repeated outbreaks or disease will be critical
factors inﬂuencing the feasibility of its application in Southeast
Asia. The pre-clinical development of recombinant HeV-sG for
use in people is only a ﬁrst step and the acquisition of further sup-
port for manufacture and clinical trials will certainly be challeng-
ing. Clinical trials will also be needed for the m102.4 human
antibody therapy, and both the United States and Australia aredeveloping the m102.4 antibody for human use as a Nipah and
Hendra virus countermeasure. Nipah virus has not occurred in
Malaysia since 1998 and requests for compassionate use of the
m102.4 antibody in India or Bangladesh following high-risk Nipah
virus exposure or cases of infection have not occurred and may
be difﬁcult to orchestrate. Whether the antibody could be pre-
positioned in Nipah virus endemic areas will largely depend on
international cooperation and ﬁnancial support.Acknowledgements
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